PARSIPPANY, N.J.— GlaxoSmithKline's diet pill, alli, is now back in most U.S. stores. Glaxo's innovation center for consumer products, in Parsippany, New Jersey, says the product package was redesigned to make tampering easier to spot. Before shipping alli, known chemically as orlistat, to retail stores, Glaxo launched it in mid-February through Drugstore.com and...» Read More
CNBC's Kate Rogers reports on the uphill battle facing potpreneurs.
Tekmira said regulators in the U.S. and Canada authorized use of its experimental drug for Ebola through an expanded access program. CNBC's Meg Tirrell provides insight.
A new survey from Mashable finds nearly 10 percent of Americans admit to smoking pot before heading into the office. CNBC's Kate Rogers shares the difficulties in testing employees.
Sept 18- Rite Aid Corp cut its full-year profit forecast for the second time in about three months due to lower margins in its pharmacy business, sending its shares down more than 16 percent.
Sept 18- Rite Aid Corp, the third-largest U.S. drugstore chain, cut its full-year profit forecast for the second time, citing lower margins in its pharmacy business, sending its shares down 11 percent in premarket trading.
Sept 18- Rite Aid Corp, the third largest U.S. drugstore chain, cut its full-year profit forecast for the second time this year as lower margins from its pharmacy business continue to eat into earnings. Rite Aid shares fell nearly 9 percent in premarket trading on Thursday after the company also shaved the top end of its sales forecast.
Avanir Pharma is up more than 60 percent, after the company said its drug was more effective in reducing agitation associated with Alzheimer's, compared with a placebo. CNBC's Meg Tirrell speaks to the company's CEO Keith Katkin.
Orexigen's obesity pill is called Contrave, and it's been approved in the U.S. CNBC's Meg Tirrell reports.
The UN food price index has dipped to a four-year low as good weather has resulted in an oversupply of cereals and dairy imports have slowed.
Walgreen is naming Jana founder Rosenstein to its board and the activist investor will get a say in choosing at least one additional director.
CNBC's Meg Tirrell reports the Drug Enforcement Administration is changing the rules around pain drugs like Vicodin. The drugs will be deemed "schedule 2 substances," versus the less restrictive "schedule 3."
CNBC's Meg Tirrell provides insight to the definition of obesity by the CDC, and which drug companies are working on treatments in the space.
A massive fire in Northern California has so far burned close to 12,000 acres and injured 12 people. CNBC's Jane Wells reports on the costs to the state, as well as to marijuana growers.
Dr. Beth Bell, CDC Infectious Diseases Center, discusses the Ebola crisis in West Africa, and the risks to U.S. citizens. Bell explains current experimental treatments.
The CDC Director is testifying before Congress on Ebola, and pharma companies are scrambling to create drugs to help. CNBC's Meg Tirrell, and Michael Yee, RBC Capital Markets, discuss some of these companies.
Viagra's patent in China has expired and some analysts expect cheaper prices will bring a surge of demand for the storied erectile dysfunction drug.
Insurance companies are hurting from the high cost of hepatitis C drug Sovaldi. Arthur Caplan, NYU Langone Medical Center, and CNBC's Bertha Coombs, share their opinions.
CNBC's Bertha Coombs reports which insurance stocks are hurting from the high cost of hepatitis C Sovaldi.
CNBC's Bertha Coombs reports which insurance stocks are feeling the pressure from high drug costs. FMHR trader Stephen Weiss advises investors to stick with Gilead.
CNBC's Scott Cohn reports FedEx has been indicted on 15 criminal counts for helping Internet pharmacies deliver drugs to buyers in the U.S. without prescriptions.